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Abstract 
 
Glycosylphosphatidylinositol (GPI) anchor biosynthesis takes place in the endoplasmic 
reticulum (ER). After protein attachment the GPI anchor is transported to the Golgi where it 
undergoes fatty acid remodeling. The ER exit of GPI anchored proteins is controlled by glycan 
remodeling and p24 complexes act as cargo receptors for GPI anchor sorting into COPII 
vesicles. In this study, we have characterized the lipid profile of mammalian cell lines that have a 
defect in GPI anchor biosynthesis. Depending on which step of GPI anchor biosynthesis the cells 
were defective we observed sphingolipid changes predominantly for very long chain 
monoglycosylated ceramides (HexCer). We found that the structure of the GPI anchor plays an 
important role in the control of HexCer levels. GPI anchor deficient cells that generate short 
truncated GPI anchor intermediates showed a decrease in very long chain HexCer levels. Cells 
that synthesize GPI anchors but have a defect in GPI anchor remodeling in the ER have a general 
increase in HexCer levels. GPI-transamidase deficient cells that produce no GPI anchored 
proteins, but generate complete free GPI anchors had unchanged levels of HexCer. In contrast, 
sphingomyelin levels were mostly unaffected. We therefore propose a model in which the 
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Introduction 
Lipid anchoring of proteins to the outer leaflet of the plasma membrane is essential for cellular 
function and development (1). One prominent lipid anchor is a complex glycolipid called 
glycosylphosphatidylinositol (GPI). The GPI anchor has the core structure phosphatidylinositol 
(PI) – glucosamine (GlcN) – (Mannose)3 – phosphoethanolamine (EtN-P) which is conserved 
among all species. After biosynthesis the GPI-anchor is attached post-translationally to the newly 
generated C-terminus of certain eukaryotic proteins destined for anchoring thereby tethering the 
protein to the membrane surface by the glycolipid moiety. GPI-anchored proteins can be released 
from the cell surface by phosphatidylinositol specific phospholipases and this cleavage event can 
induce major conformational changes on the GPI-anchored protein itself (2).  
At least three organelles, endoplasmic reticulum (ER), Golgi and peroxisomes are involved in 
the biosynthesis and remodeling of the GPI anchor. The biosynthesis is initiated on the outer side 
of the endoplasmic reticulum membrane. After the first two reactions the GPI-anchor precursor 
is flipped and biosynthesis continues on the luminal side of the ER where the diacyl chains of 
phosphatidylinositol are then replaced by alkyl-acyl chains. This step is impaired in mutants of 
the peroxisomal alkyl phospholipid biosynthesis pathway (3).  
After protein attachment, the GPI anchor undergoes complex remodeling that begins in the ER 
with the removal of the inositol–linked acyl chain (4) and the remodeling of the GPI glycan part 
(5). Glycan remodeling is crucial for sorting of GPI anchored proteins into ER exit sites and their 
subsequent ER to Golgi transport (6). In mammalian cells remodeling of the GPI anchor is then 
continued in the Golgi where the unsaturated fatty acid of the GPI anchor is replaced by a 
saturated fatty acid chain (7). From the Golgi compartment, GPI-anchored proteins are  
transported to the plasma membrane where they are thought to associate preferentially with 
	   4	  
glycosphingolipids and cholesterol to be enriched in lipid ordered microdomains. Lipid 
remodeling is likely to be important for this association because unremodeled GPI-anchored 
proteins, which carry unsaturated fatty acids, are no longer enriched in detergent resistant 
membrane fractions (7). Treatments that deplete either membrane cholesterol or sphingolipids 
also disrupt the association of GPI anchored proteins with detergent-resistant membranes 
(DRMs) further supporting the notion that specialized domains are critical for the correct 
localization of this subset of proteins (8, 9).  
Importantly, trafficking of GPI anchored proteins is affected by alterations in sphingolipids and 
sterols. In yeast, the ER to Golgi transport of GPI anchored proteins is rapidly reduced by 
inhibition of de novo sphingolipid biosynthesis without affecting the transport of soluble or 
transmembrane proteins (10, 11). However, GPI anchored proteins might play an important role 
in the transport of membrane proteins such as Tat2 and Fur4p which are no longer associated 
with DRMs and are retained in the ER in  v cells that are deficient at an early stage of GPI 
anchor biosynthesis (12). In mammalian cells it was shown that inhibition of sphingolipid 
biosynthesis affects apical targeting of GPI-anchored proteins in Madin-Darby canine kidney 
(MDCK) cells (13) and sorting of the axonal GPI-anchored protein Thy-1 in primary 
hippocampal neurons (14). However unlike yeast, ER-to-Golgi transport of GPI-APs in 
mammalian cells does not depend on de novo sphingolipid biosynthesis (15). 
An important characteristic of sphingolipid trafficking is the coexistence of at least two different 
ceramide transport pathways, a major ATP and cytosol dependent pathway and a minor ATP or 
cytosol-independent pathway (16). Evidence for two different ceramide transport pathways was 
first obtained with the isolation of the CHO mutant cell line LY-A that shows a defect in 
sphingomyelin but not in HexCer biosynthesis (17) and the subsequent identification of a 
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ceramide transport protein called CERT (18). Two pathways for ceramide transport also exist in 
yeast (19).  
As changes in lipid composition affect GPI anchored proteins, we asked whether a lack of GPI-
anchored proteins together with the abnormal accumulation of GPI-anchor intermediates would 
affect the lipid profile of mammalian cells. To address this question, we made use of a series of 
mutant Chinese hamster ovary (CHO) cell lines (1) that have defects along the GPI-anchor 
biosynthesis pathway. We determined the lipid profile of the GPI anchor deficient cells using a 
lipidomics approach. Lipidomics has emerged in the era of genomics and proteomics as a rapidly 
expanding research field due to recent advances in mass spectrometry and bioinformatics. Here, 
we applied tandem mass spectrometry coupled with multiple reaction monitoring (MRM) to 
detect and quantify over 850 phospho- and sphingolipids from GPI anchor deficient cells. Using 
the same crude lipid extracts, we analyzed complex glycosphingolipids by a non-targeted mass 
spectrometry approach and also investigated the sterol composition of each sample by GC-MS. 
 
Materials and Methods  
Chemicals and lipid standards 
DLPC 12:0/12:0 (850335), PE 17:0/14:1 (PE31:1, LM-1104), PI 17:0/14:1 (PI31:1, LM-1504), 
PS 17:0/14:1 (PS31:1, LM-1304), C17:0 ceramide (860517), C12:0 SM (860583) and Glucosyl 
C8:0 Cer (860540) were used as internal lipid standards and were purchased from Avanti Polar 
Lipids Inc (Alabaster, Alabama, USA). Ergosterol was used as sterol standard and was purchased 
from Fluka (Buchs, Switzerland). 
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Methyl tert-butyl ether (MTBE) was from Fluka (Buchs). Methylamine (33% in absolute 
ethanol) was from Sigma Aldrich (Steinheim, Germany). HPLC grade chloroform was purchased 
from Acros (Geel, Belgium), LC-MS grade methanol and LC-MS grade ammonium acetate were 
from Fluka. LC-MS grade water was purchased from Biosolve (Valkenswaard, Netherlands).  
 
Cell culture and transfection 
All CHO cell lines used in this study were from the laboratory of Taroh Kinoshita (1). Cells of 
the F21 background stably express the GPI anchor marker proteins CD59 and DAF and twelve 
proteins involved in GPI anchor biosynthesis (20) whereas cells of the C311 background express 
four proteins of the GPI anchor biosynthesis pathway in addition to the markers CD59 and DAF 
(21-23). Presence of those plasmids was verified by antibiotic resistance of cells to G418, 
hygromycin B and blasticidin S (F21 series) or resistance of cells to G418, hygromycin B and 
puromycin (C311 series). For lipid extraction, cells were maintained in Ham’s F-12 medium 
(Invitrogen) supplemented with 10 % fetal calf serum (FCS) and 1 % PS (penicillin (50 U/ml) 
and streptomycin (50 U/ml), Invitrogen). HeLa cells were maintained in DMEM (Invitrogen) 
with 10 % FCS supplemented with 1 % PS. All cells were grown at 37 °C and 5 % CO2. 
HeLa cells were transiently transfected with siRNA using Lipofectamine RNAiMAX 
(Invitrogen) according to the manufacturer’s instructions. Human ON-TARGETplus 
SMARTpool siRNA for PIG-L (L-011953-01-0005), DPM3 (L-017492-02-0005), PIG-X (L-
013784-02-0005), PIG-F (L-011753-01-0005), PIG-O (L-008728-01-0005), PIG-U (L-017428-
00-0005), PGAP1 (L-008110-01-0005), PGAP5 (L-008547-01-0005), p23 (L-003718-00-0005), 
p24 (L-008074-01-0005), CERT (L-012101-00-0005) and control scrambled siRNA (ON-
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TARGETplus non-targeting Pool D-001810-10-05) were purchased from Thermo Scientific. 
GeneSolution siRNA against PGAP2 (1027416) was purchased from Qiagen. 
Stable CHO transfectants expressing human PIG-F or PIG-U respectively together with the 
Venus-FLAG-CD59 construct were established by transfection with Lipofectamine 2000 
(Invitrogen) followed by selection with Zeocin (300 µg/ml, Invitrogen) for two weeks. Single 
clones were isolated, expanded and analyzed for CD59-Venus surface expression as a marker for 
restored GPI anchor biosynthesis.  
 
Plasmids 
Using the EcoRI / NotI restriction sites human PIG-F and PIG-U were subcloned from pMEori-
PIG-F and pME-PIG-U (20) into the pcDNATM3.1/Zeo(+) mammalian expression vector 
(Invitrogen). Constructs were verified by sequencing. Vector pME-puro-Venus-FLAG-CD59 
(15) was obtained from the laboratory of Reika Watanabe (University of Geneva, Switzerland). 
 
RNA isolation and quantitative RT-PCR 
Total RNA was isolated from HeLa cells 72 h after transfection using the RNeasy MINI kit 
(Qiagen) according to the manufacturer’s instructions. RNA was converted into cDNA using 
random hexamers and Superscript II reverse transcriptase (Invitrogen). qRT-PCR was carried out 
on a BIO-RAD iCycler machine (BioRad, Hercules, CA, USA) with the ABsoluteTMQPCR 
SYBR Green reagent (Thermo Scientific). Results were normalized against TBP expression. All 
primers except for PIG-U, PGAP1 and PGAP5 were designed using the NCBI Primer BLAST 
web tool. The following primer were used: PIGL.For 5'-GGGTGCTCTGTGCTCACGCT-3', 
PIGL.Rev 5'-TGGCTTTCTTGGCCTGTGCCA-3'; DPM3.For 5'-
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GGCCACTGCCCGCCTACTTG-3', DPM3.Rev 5'-GTCGGCTCGGGCCTCCTGTA-3'; 
PIGX.For 5'-GCTCTGACGCCGGCATAAGGG-3', PIGX.Rev 5'-
GACGGCAGGTGTGCAAGTCCTC-3'; PIGF.For 5'-GCCGCCCGTCGTACCTGATG-3', 
PIGF.Rev 5'-TGGCTAGCTAACTCTCCCTCCCG-3'; PIGO.For 5'-
CACCACCATGCAGCGCCTCA-3', PIGO.Rev 5'-CGCCTTCCTGCACTGGTGAGC-3'; 
PGAP2.For 5'-GCTGGAGTGTACACCATCTTTGCC-3', PGAP2.Rev 5'-
CCGAAGTCCCACCAGGCCGT-3'; CERT.For 5'-AGGCTGTCATCACACCTCACGA-3', 
CERT.Rev 5'-AGCCATGTCGACGCAAGCTGG-3'; p23.For 5'-
TGCGCAGCCACCTCAAGATCAC-3', p23.Rev 5'-CGCCCTGTTCCCTTGCTCTCA-3'; 
p24.For 5'-TCGACGTGGAGATTACAGGACCA-3', p24.Rev 5'-
TGGAGTCATGGTGGACATCCGGT-3'; TBP.For 5'-CCGAATATAATCCCAAGCGGT-3', 
TBP.Rev 5' AAATCAGTGCCGTGGTTCGT-3'. For PIG-U, PGAP1 and PGAP5 pre-designed 
primersets from Qiagen (QuantiTect Primer Assay) were purchased. Relative CHOP and BiP 
mRNA levels were measured against TBP expression by qRT-PCR using primer: CHOP.For 5'-
AGAACCAGGAAACGGAAACAGA-3'; CHOP.Rev 5'-TCTCCTTCATGCGCTGCTTT-3'; 
BiP.For 5'-TGTTCAACCAATTATCAGCAAACTC-3'; BiP.Rev 5'-
TTCTGCTGTATCCTCTTCACCAGT-3' (24). The efficiency of each primer set was 
determined to be between 90-100 %.  
 
Lipid extraction protocols 
Lipid extracts were prepared using the MTBE protocol (25). Briefly, 2.5 x 106 cells were 
resuspended in 100 µl H2O. The cell suspension was transferred into a 2 ml Eppendorf tube. 
360 µl methanol and a mix of internal standards was added (400 pmol DLPC, 1000 pmol 
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PE31:1, 1000 pmol PI31:1, 3300 pmol PS31:1, 2500 pmol C12SM, 500 pmol C17Cer and 
100 pmol C8GC). Samples were vortexed and 1.2 ml of MTBE was added. Samples were placed 
for 10 min on a multitube vortexer at 4 °C (Lab-tek International, Christchurch, New Zealand) 
followed by an incubation for 1h at room temperature (RT) on a shaker. Phase separation was 
induced by addition of 200 µl MS-grade water. After 10 min of incubation at RT samples were 
centrifuged at 1000 g for 10 min. The upper (organic) phase was transferred into a 13 mm glass 
tube (Corning) with a Teflon-lined cap and the lower phase was re-extracted with 400 µl of a 
MTBE/MeOH/H2O mixture (10:3:1.5). Samples were vortexed, incubated for 10 min at RT and 
centrifuged for 10 min at 1000 g. The upper phase was collected and the combined organic 
phases were dried in a CentriVap Vacuum Concentrator (Labconco, MO, USA). In total 1500 µl 
of organic phase was recovered from each samples and split into three parts. One part was 
treated by alkaline hydrolysis to enrich for sphingolipids and the other two aliquots were used for 
glycerophospholipid and sterol analysis, respectively. 
Glycerophospholipids were deacylated according to the method by Clarke (26). Briefly, 1 ml 
freshly prepared monomethylamine reagent (methylamine/H2O/n-butanol/methanol at 5/3/1/4 
(vol/vol)) was added to the dried lipid extract and then incubated at 53 °C for 1 h in a water bath. 
Lipids were cooled to RT and then dried in a CentriVap Vacuum Concentrator. For desalting, the 
dried lipid extracts were resuspended in 300 µl water-saturated n-butanol. The extracts were 
sonicated and then extracted with 150 µl H2O. The organic phase was collected, and the aqueous 
phase was re-c xextracted twice with 300 µl water-saturated n-butanol. The organic phases were 
pooled and dried in a CentriVap Vacuum Concentrator. 
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Determination of total phosphorus 
The dried glycerophospholipid extract was resuspended in 250 µl chloroform/methanol (1:1) and 
100 µl were placed into a 13 mm disposable pyrex tube. The solvent was completely evaporated 
to avoid inhibition of the reaction by organic solvents. 0, 2, 5, 10, 20 µl of a 3 mM KH2PO4 
standard solution were placed into separate pyrex tubes. To each tube 20 µl of water and 140 µl 
of 70 % perchloric acid were added. Tubes were heated at 180 °C for 1 h in a hood. Tubes were 
removed from the heat block and kept at RT for 5 min. Then 800 µl of freshly prepared H2O / 
1.25 % NH4Molybdate (50 mg/4 ml H2O) / 1.67 % ascorbic acid (100 mg/6 ml H2O) in the ratio 
of 5:2:1 were added. Tubes were heated at 100 °C for 5 min with a marble on each tube to 
prevent evaporation during heating. Tubes were removed from the block and cooled at RT for 
5 min. 100	  µl of each sample was then transferred into a 96-well microplate and the absorbance 
at 820 nm was measured. 
 
Phospho-and Sphingolipid analysis by tandem mass spectrometry 
Tandem mass spectrometry for the identification and quantification of phospho- and sphingolipid 
molecular species was performed using multiple reaction monitoring (MRM) with a TSQ 
Vantage Triple Stage Quadrupole Mass Spectrometer (Thermo Scientific) equipped with a 
robotic nanoflow ion source, Nanomate HD (Advion Biosciences, Ithaca, NY). Each individual 
ion dissociation pathway was optimized with regard to collision energy. Lipid concentrations 
were calculated relative to the relevant internal standards as described in (27) and then 
normalized to the total phosphate content of each total lipid extract to adjust for difference in cell 
size, membrane content and extraction efficiency. 
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Cellular ceramide glycosylation assay 
The cellular ceramide glycosylation assay was performed as described previously (28). Briefly, 
HeLa cells were treated with siRNA against PIG-F, PIG-O or PIG-U for 70h. Scrambled (SCR) 
siRNA was used as control. Cells were then switched to 950 µl of 1% BSA DMEM medium 
containing 10 µM NBD C6-ceramide for 2h. Cells were then rinsed with ice-cold PBS, scraped 
and pelleted. Sphingolipids were extracted using the MTBE/methylamine protocol. Samples 
were resolved on partisil HPTLC plates with fluorescent indicator (Whatman). To distinguish 
GalCer and GlcCer the HPTLC plates were impregnated with borate as described previously 
(28). After dipping the plates into a 1% aqueous sodium tetraborate solution the HPTLC plates 
were activated at 120° C for 30 min. Sphingolipids were resolved with the solvent system of 
chloroform/MeOH/H2O (100:30:4). Fluorescent lipids were visualized under UV exposure. NBD 
C6-Cer and NBD C6-Cer complexed to BSA were purchased from Invitrogen, NBD C6-GlcCer 
and NBD C6-GalCer were purchased from Matreya. Bands were quantified with the Image J 
software and values were calculated as percentage of input (NBD C6-Cer). 
 
Determination of GM3 levels  
Individual GM3 species were detected by high resolution mass spectrometry on the LTQ 
Orbitrap XL linear ion trap (Thermo Scientific). Sphingolipid enriched extracts were infused at a 
low flow rate using the TriVersa NanoMate robotic ESI source (Advion Biosciences) equipped 
with a standard ESI chip (Advion Biosciences). Samples were analyzed in negative ion mode. 
Individual GM3 species were identified by their parental mass combined with fragmentation. 
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Product ions of m/z 290 were obtained from HCD fragmentation of the GM3 precursor ions. 
These ions correspond to Neu5Ac fragments obtained after cleavage of the glycosidic bond. 
 
Sterol analysis by gas liquid chromatography mass spectrometry.  
Extracts were analyzed by GC–MS as described (29). Briefly, samples were injected into a 
VARIAN CP-3800 gas chromatograph equipped with a Factor Four Capillary Column VF-5ms 
15 m × 0.32 mm i.d. DF = 0.10 and analyzed by a Varian 320 MS triple quadrupole with electron 
energy set to – 70 eV at 250 °C. Samples were applied with the column oven at 45 °C, held for 
4 min, then raised to 195 °C (20 °C/min). Sterols were eluted with a linear gradient from 195 to 
230 °C (4 °C / min), followed by raising to 320 °C (10 °C / min). Finally, the column 
temperature was raised to 350 °C (6 °C / min) to elute sterol esters. Cholesterol and cholesterol 
esters were identified by their retention times (compared to standards) and fragmentation 
patterns, which were compared to the NIST library. 
 
Statistical analyses 
All results are representative of at least 3 independent experiments. Statistical analyses were 
performed using an unpaired Student’s t-test. Differences were considered significant for p < 
0.05 (*), p < 0.01 (**) and p < 0.005 (***). 
	   13	  
Results 
The goal of this study was to establish the lipid profile of cells that have a defect in GPI-anchor 
biosynthesis. CHO GPI-anchor mutants have been very useful in the past to understand the GPI 
biosynthesis pathway and have allowed cloning of the majority of genes involved in this process 
(1). We focused on CHO mutants that had either the F21 or the C311 genetic background. The 
F21 series includes cell lines that are defective in Dol-P-Mannose synthase (DPM3), GPI 
mannosyltransferase I (PIG-X), ethanolamine phosphate transferase II and III (PIG-F) and GPI 
lipid remodeling (PGAP2). From the C311 series we analyzed cells defective in ethanolamine 
phosphate transferase III (PIG-O) and GPI transamidase (PIG-U).  
 
Defects in GPI anchor biosynthesis lead to changes in HexCer levels. 
As can be seen in Figure 1 we observed changes in HexCer levels in CHO mutant cells that have 
a defect in GPI anchor biosynthesis. Since CHO cells do not possess endogenous GalCer (30) the 
changes in HexCer are due to a difference in their glucosylceramide (GlcCer) levels. In detail, 
we observed a downregulation of total GlcCer levels in a subset of GPI anchor mutants (DPM3, 
PIG-X and PIG-F) that generate short truncated GPI anchor intermediates. To our surprise we 
did not see an effect in GPI anchor mutant PIG-U cells (Fig. 1B). Since PIG-U mutant cells 
(PA16.1) have no expression of the GPI marker protein CD59 and only 1% remaining DAF 
expression (Supplemental table 1) this indicates that the observed GlcCer changes are not due to 
a general absence of GPI anchored proteins (23). Lipid remodeling in the Golgi also did not 
influence GlcCer levels since we did not observe a change in PGAP2 deficient cells (Fig. 1A), 
which have normal GPI anchor biosynthesis in the ER but greatly reduced surface expression 
levels of CD59 and DAF (31) due to rapid secretion (Supplemental table 1). In contrast, the GPI 
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anchor mutant PIG-O (22), which shows a great reduction but not a complete deficiency in the 
surface expression of GPI anchored proteins displayed a strong increase in GlcCer-levels 
(Supplemental table 1, Fig. 1B). 
When GlcCers were analyzed in detail we observed an effect concerning the chain length of 
individual glucosylceramide species. Very long chain GlcCers with a fatty acid chain length of 
C22 and C24 were strongly decreased in the GPI anchor mutants DPM3, PIG-X and PIG-F 
whereas GlcCer species with a fatty acid chain length between C10 and C20 were mostly 
unaffected (Fig. 1C). In contrast, PIG-O mutant cells showed a general upregulation of all 
glucosylceramide species regardless of their chain length (Fig. 1D). 
We next focused on the GPI anchor mutants PIG-F and PIG-U, which showed different 
phenotypes in our lipid analysis. Both GPI-anchor mutants cannot generate GPI-anchored 
proteins and accumulate free GPI-anchor intermediates that are similar in structure (Fig. 2A). 
However, PIG-U mutants are deficient in one subunit of the GPI transamidase and accumulate 
otherwise a functional free GPI anchor. PIG-F mutants on the other hand lack the regulatory 
subunit of the EtN-P transferases II and III and consequently have no EtN-P on both Man2 and 
Man3. The EtN-P on Man2 is later recognized and removed by PAGP5, a step which is 
necessary for efficient incorporation of GPI anchored proteins in to ER exit sites (5). PIG-F and 
PIG-U mutants belong to different series of CHO mutant cells (F21 and C311 respectively) and 
carry plasmids, which encode for several GPI anchor biosynthesis enzymes and GPI anchor 
marker proteins (20, 23). To test if the observed GlcCer changes are due to the defect in GPI 
anchor biosynthesis or if they are connected to their genetic background, we stably 
complemented both PIG-F and PIG-U mutant cells with the corresponding wild-type gene. In 
order to monitor restored GPI anchor biosynthesis we stably coexpressed Venus tagged CD59. 
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As can be seen in Fig 2B, the GPI anchored protein CD59 localizes to the cell surface in PIG-F 
complemented cells whereas in the PIG-F deficient control cells, CD59 does not reach the cell 
surface. We then analyzed the lipid profile from both uncomplemented and complemented cells. 
As can be seen in Fig. 2C GlcCer levels returned to wild type in the complemented PIG-F cells 
indicating that the decrease in GlcCer levels was due to their defect in GPI anchor biosynthesis. 
As expected, we did not observe any changes in PIG-U cells after complementation (Fig. 2C). 
We next wanted to see whether the observed sphingolipid changes are CHO cell specific or if 
they can be reproduced in another mammalian, preferentially human cell line. In addition, we 
were interested if a transient knockdown of GPI anchor biosynthesis leads to the same 
sphingolipid changes as a genetic mutation. To test these two parameters, we transiently silenced 
PIG-L, DPM3, PIG-X, PIG-F, PIG-O, PIG-U and PGAP2 expression in HeLa cells by siRNA. 
The gene silencing efficiency was confirmed by quantitative RT-PCR (Supplement S1). Hela 
cells possess ceramide galactosyltransferase activity (32) therefore their HexCer levels might be 
composed of GlcCer and GalCer species. When analyzed by HPTLC, HeLa cells showed higher 
levels of GlcCer than GalCer (Supplement S2). As can be seen in Figure 3A we found a decrease 
in total HexCer levels in PIG-L, DPM3, PIG-X and PIG-F but not in PIG-U or PGAP2 deficient 
cells. Again very long chain C22 and C24 HexCer species were strongly affected whereas C16 
HexCer was only slightly decreased (Fig. 3B). Since HeLa cells have a higher percentage of very 
long chain C22 and C24 HexCer species than CHO cells, the decrease in total HexCer was more 
pronounced. A specific decrease of very long chain HexCer species was also observed for the 
less abundant sphinganine containing dihydroglycosylceramides (DHHexCer, Supplement S3). 
Interestingly, PIG-O depleted cells showed again a strong increase in total HexCer levels and a 
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general upregulation of all HexCer species similar to what had been observed for CHO cells 
(Fig. 3A, B).  
 
Decrease in HexCer affects downstream glycosphingolipids. 
We next analyzed if the observed decrease in GlcCer levels in CHO cells also affects 
downstream glycosphingolipids such as GM3. The glycosphingolipid profile of CHO cells is 
rather simple since they only synthesize GlcCer, lactosylceramide and the ganglioside NeuAcα2-
3Galβ1-4Glcβ1-1Cer (GM3) (30). CHO cells accumulate high amounts of GM3 since they are 
unable to synthesize GM2 and other complex gangliosides such as GM1 and GD1a (33). We 
therefore measured GM3 levels in the GPI anchor mutant CHO cells. When individual GM3 
species were analyzed by high-resolution mass spectrometry we found a decrease of the very 
long chain GM3 species for DPM3, PIG-X and PIG-F but not for PGAP2 deficient cells (Fig. 
4A). GM3 levels also did not change in PIG-O and PIG-U deficient cells indicating that the 
increase in GlcCer levels that was observed in PIG-O deficient cells did not translate into an 
upregulation of GM3 (Figure 4B). HeLa cells predominantly synthesize Gb3 and have low 
amounts of GM3 (34), which were below our quantification level. 
 
Ceramide levels are affected by defects in GPI anchor biosynthesis in a cell line dependent 
manner. 
Since ceramides are direct precursors of monoglycosylated ceramides we analyzed if the 
observed effect on HexCer levels was reflected by a decrease in ceramide. We measured 
ceramide levels in the same set of GPI anchor mutant CHO cells and found that DPM3, PIG-X 
and PIG-F cells had reduced ceramide levels whereas no change was observed for PGAP2 
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deficient cells (Fig 5A). On the individual level very long chain ceramides, in particular C24 
ceramide were decreased (Fig 5C). In PIG-U and PIG-O mutant cells, ceramide levels were 
unaffected (Fig. 5B and D). In HeLa cells however, total ceramide levels were not decreased 
upon knockdown of PIG-L, DPM3, PIG-X or PIG-F (Fig. 5E) and also on the individual level 
there was no significant change in very long chain ceramides (Fig. 5F). This indicates that the 
decrease in very long chain ceramides could be cell line specific or might be a compensatory 
effect of the genetic mutation. In addition, it also raises the possibility that reduced ceramide 
biosynthesis is not the only cause for the observed decrease in HexCer levels. We next tested if 
glycosylation of ceramide is affected in the GPI anchor deficient cells. It has been shown that 
glucosylceramide synthase localizes to the Golgi in HeLa cells (35) but it cannot be fully ruled 
out that some GlcCer synthase activity might also exist in the ER (36). To test if ceramide 
glycosylation is affected in the GPI anchor deficient cells we performed an in vivo ceramide 
glycosylation assay (28). As can be seen in Figure 5G NBD-C6 ceramide was efficiently 
converted into GlcCer in PIG-F, PIG-O and PIG-U depleted cells. There was however no 
synthesis of GalCer, which shows that ceramide galactosyltransferase activity is very low in 
HeLa cells (Fig. 5G). Relative to the total amount of input (NBD-C6 Cer) there was an increase 
in NBD-C6 GlcCer in the PIG-O depleted cells, which indicates more GlcCer synthase activity 
in PIG-O depleted cells. 
 
Very long chain sphingomyelin levels are partially affected in GPI anchor deficient cells 
In contrast to the observed changes in HexCer and ceramide, total sphingomyelin levels were not 
affected in the same set of GPI anchor mutant CHO cells (Fig. 6A and B). Total sphingomyelin 
levels also did not change in both the PIG-F and the PIG-U complemented cells (Supplement 
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S4). However, CHO cells have predominantly C16 sphingomyelin, which accounts for 70% of the 
total sphingomyelin and very long chain sphingomyelins were slightly reduced in CHO mutants 
that have a decrease in GlcCer levels (Fig. 6C). Total sphingomyelin levels were also not 
significantly changed in HeLa cells (Fig. 6D) but the detailed analysis showed that defects in 
GPI anchor biosynthesis have an effect on very long chain sphingomyelins (Fig. 6E). As there is 
much more sphingomyelin than HexCer in both, CHO and HeLa cells, the absolute amounts of 
sphingomyelin that are affected could be in fact more than HexCers. 
The ceramide transport protein CERT mediates transport of ceramide for sphingomyelin 
biosynthesis. However, CERT deficiency does not affect total GlcCer levels in CHO cells 
indicating that there is an alternative ceramide transport pathway for the biosynthesis of GlcCer 
(18). In vitro CERT has a strong preference for the transport of ceramides that are C20 or shorter 
and does not efficiently transport very long chain ceramides (37). We silenced CERT in HeLa 
cells and observed a decrease in total sphingomyelin as expected (Fig. 7A). HexCer levels did 
not decrease and even modestly increased which confirms the existence of different ceramide 
transport pathways (Fig. 7A). As shown in Figure 7B knockdown of CERT affected both C16 and 
C24 sphingomyelins indicating that in vivo CERT is also required for the efficient transport of 
very long chain ceramides. This might explain why very long chain sphingomyelins are only 
partially affected in GPI anchor deficient cells. Individual HexCer levels showed a stronger 
increase in C16 than in C22 glycosylceramides (Supplement S5).  
 
Defects in GPI glycan remodeling or GPI anchor trafficking affect HexCer levels. 
We had noticed a strong global increase in HexCer levels for PIG-O deficient CHO cells, which 
was reproduced in HeLa cells during a transient knockdown of PIG-O. In PIG-O deficient cells 
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ethanolamine phosphate transferase III (PIG-F/GPI7) is active and cells can attach EtN-P onto 
mannose 2, which is important for glycan remodeling. Interestingly PIG-O mutants are not 
completely deficient in the surface expression of GPI-anchored proteins and accumulate an 
intermediate, called KO-2 (Figure 2A), which is competent for protein attachment but has an 
abnormal glycan structure (38). The glycan structure plays an important role for sorting of GPI 
anchored proteins into ER exit sites (5, 6) and only glycan remodeled GPI-anchored proteins 
associate with p24 family proteins (6, 39). We therefore analyzed the lipid profile of cells in 
which the GPI remodeling enzymes PGAP1, PGAP5 or the p24 family members p23 or p24 
were silenced respectively. As can be seen in Figure 8A total HexCer levels increased upon 
knockdown of PGAP1, PGAP5, p23 and in particular for p24. Individual HexCer levels showed 
that all HexCer species were affected equally (Fig. 8B). This result is in line with the observed 
increase of HexCer levels in PIG-O deficient cells and indicates that an abnormal GPI structure 
or a delay in ER to Golgi transport can lead to an increase in total HexCer levels. We also 
observed some increase in ceramide levels in particular for PGAP1 but sphingomyelin levels 
were not changed (Supplement S6, S7). In yeast it has been shown that a defect in GPI anchor 
remodeling or trafficking results in ER stress and induces the upregulation of the unfolded 
protein response (UPR) (40-42). We assessed ER stress by measuring transcriptional activation 
of the UPR. The C/EBP homology protein (CHOP), which is involved in ER stress mediated 
apoptosis was upregulated in the GPI anchor mutant PIG-O, the remodeling mutants PGAP1 and 
PGAP5 as well as in p23 and p24 knockdowns but not in PIG-F deficient cells (Figure 8C). The 
ER chaperone BiP, was upregulated in PIG-O, PGAP5 and p23 depleted cells. 
 
Cholesterol ester levels are reduced in cells that do not synthesize GPI anchored proteins 
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It has been previously reported that GPI-deficient CHO cells have cholesterol contents similar to 
wild type CHO cells (43). Using our mass spectrometry approach we measured the amount of 
free cholesterol and of cholesterol ester in the GPI-anchor deficient CHO and HeLa cells. As can 
be seen in Figure 9A free cholesterol levels are unchanged between wild type and the GPI anchor 
mutants. We found, however, that all GPI-anchor mutant cells including PIG-U had lower levels 
of cholesterol ester than the corresponding wild type cells (Fig. 9A). PIG-O mutant cells, which 
are not completely deficient in the biosynthesis of GPI anchored proteins, did not show a 
reduction in cholesterol esters. We then also analyzed the sterol composition of HeLa cells in 
which PIG-L, DPM3, PIG-F, PIG-O or PIG-U had been silenced respectively. Under these 
conditions, we observed a similar result: free cholesterol levels were mostly unchanged (Fig. 9B) 
whereas cholesterol ester levels were strongly reduced in all knockdowns except PIG-O (Fig. 
9B). This result suggests that the observed effect on cholesterol ester is due to the inability to 
synthesize certain GPI anchored proteins and is not caused by a specific GPI anchor intermediate 
that is generated. 
In parallel to the observed changes in glycolipids and sterols we also analyzed the phospholipid 
content of each GPI anchor mutant by mass spectrometry. We measured the levels of 
phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylinositol (PI) and 
phosphatidylserine (PS). Among those glycerophospholipids we did not observe any major 
changes except for a mild increase of total PE in the GPI-anchor mutants DPM3, PIG-X and 
PIG-O (Supplement S8).  
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Discussion 
In this study we show that GPI-anchor biosynthesis mutants that generate incomplete GPI anchor 
intermediates have a strong decrease in very long chain C22 and C24 glucosylceramide levels, 
without greatly affecting long chain C16 glucosylceramides. In contrast, GPI transamidase 
deficient cells (PIG-U) that synthesize complete anchors, but do not attach them to proteins, do 
not show this effect. This suggests that the GPI anchor, not necessarily attached to proteins, 
regulates very long chain GlcCer levels. Complementation experiments showed that these 
changes are specific to the GPI anchor biosynthesis and are not due to the complex genetic 
background of the GPI anchor mutant cells. siRNA silencing of GPI anchor biosynthesis genes 
in HeLa cells demonstrated that the observed effects on GlcCers are not restricted to one cell 
type and that the strategy of siRNA gene downregulation can be used to see changes in lipid 
profiles in a relatively short time period.  
In addition to the decrease in GlcCer we also observed a decrease in very long chain ceramides 
in the CHO GPI anchor mutants. However this decrease was not observed in HeLa cells 
following a transient knockdown of the same GPI anchor biosynthesis genes (Fig. 5E). This 
implies that the decrease in very long chain HexCer is probably not just the consequence of 
reduced ceramide levels.  
Defects in GPI anchor biosynthesis lead to the ER accumulation of GPI anchor intermediates 
such as GlcNAc-PI and GlcN-acyl-PI as well as the mannose containing GPI intermediates H2-
H8 (1). Metabolic labeling with myo-[3H]inositol has shown that GPI anchor mutants such as 
DPM3 and PIG-X accumulate moderate amounts of the early GPI anchor intermediate GlcN-
acyl-PI whereas PIG-U mutants show a high ER accumulation of all GPI anchor intermediates 
(20, 23). In particular, Man-GlcN-(acyl)-PI labels strongly in PIG-U deficient cells cultured with 
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[3H]mannose, suggesting that GlcN-(acyl)-PI is also elevated in those cells (23). Since GlcCer 
levels were unaffected in PIG-U deficient cells it is therefore unlikely that the ER accumulation 
of GPI anchor intermediates is causing an inhibition of certain ceramide synthases or that GlcCer 
synthase activity would be affected. Another possible reason for reduced ceramide and HexCer 
levels could be that ER to Golgi transport of ceramide is linked to the transport of GPI anchored 
proteins and free GPI anchor molecules. If very long chain ceramides are not transported 
efficiently from the ER and are locally accumulating this could lead to a feedback inhibition of 
certain ceramide synthases and subsequently to a decrease in HexCers. The degree of feedback 
inhibition might be different in HeLa versus CHO cells. 
In contrast to HexCer, sphingomyelin levels were mostly unaffected in the GPI anchor deficient 
cells. When analyzed in detail we found that CHO cells have primarily C16 sphingomyelin (Fig. 
6C). In contrast, HeLa cells have a much higher content of very long chain sphingomyelins (C24 
sphingomyelin is about 45% of total sphingomyelin) and very long chain sphingomyelin levels 
were mildly affected in HeLa cells (Fig. 6E). The major fraction of ceramide in mammalian cells 
is transported to the Golgi in a non-vesicular manner via the ceramide transport protein CERT 
and mutants in CERT affect mainly sphingomyelin levels, which suggested an alternative 
mechanism of transport of ceramide destined for GlcCer biosynthesis (18). CERT has a 
preference for ceramide species with an acyl chain length of C20 or less and transports C22 and 
C24 ceramide with greatly reduced efficiency in vitro (37). However our results show that 
knockdown of CERT led to a global decrease of all sphingomyelin species and also greatly 
reduced C24 sphingomyelin (Fig. 7B). We therefore conclude that in vivo the transport of very 
long chain ceramides from ER to Golgi for sphingomyelin biosynthesis is regulated by CERT. 
Interestingly, ER to Golgi trafficking of GPI anchored proteins is normal in CERT deficient cells 
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(44). Taken together these data support a model in which GPI anchor molecules regulate the 
transport of very long chain ceramides destined for GlcCer and to some degree also for 
sphingomyelin biosynthesis. 
A common feature among the mutants that show decreased levels of very long chain GlcCer is 
the accumulation of GPI anchor precursors that have incomplete glycan structures. The GPI 
anchor mutants PIG-L, DPM3 and PIG-X produce very short truncated GPI anchor intermediates 
(GlcNAc-PI, GlcN-(acyl)-PI) that are unlikely to leave the ER. The mutant PIG-F however 
generates a GPI anchor intermediate that possesses an almost complete glycan structure but still 
has reduced GlcCer levels (Fig. 2A). PIG-F is the regulatory subunit of the GPI EtN-P 
transferase II (PIG-O/PIG-F) and III (GPI7/PIG-F) (45). Consequently, both EtN-P transferases 
are not active in PIG-F deficient cells (38) and mutant cells do not attach EtN-P onto mannose 2 
or 3 (46). Since EtN-Ps are important for glycan remodeling and ER to Golgi transport we 
speculate that this abnormal glycan structure makes it impossible for the PIG-F GPI anchor 
intermediate to exit the ER.  
In contrast, PIG-U deficient cells, which make a complete GPI-anchor but lack the enzymatic 
activity to transfer the free GPI anchor to a protein, have unchanged levels of HexCer. 
Interestingly, it has been reported that cells generate large pools of free non-proteins linked GPI 
anchors that exit the ER and are transported to the cell surface (47, 48). While there is no direct 
evidence that free GPI anchors can be remodeled in vivo, it has been shown that free GPI anchors 
are substrates for remodeling enzymes in vitro (5).  
In contrast to the mutants PIG-L, DPM3, PIG-X and PIG-F we observed a strong increase in 
HexCer levels for the GPI anchor mutant PIG-O. This was observed in both, the CHO cell lines 
as well as HeLa cells under siRNA silencing conditions. PIG-O mutants generate intermediates 
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with a similar GPI structure as PIG-F. However, the ethanolamine phosphate transferase II, 
which is a complex of GPI7 and PIG-F is active in PIG-O deficient cells (45). Ethanolamine 
phosphate transferase II adds EtN-P onto mannose 2, which is important for glycan remodeling 
by PGAP5 (5). Interestingly PIG-O mutants are not completely deficient in the surface 
expression of GPI-anchored proteins (38). The surface expression of PIG-O deficient cells is due 
to a minor GPI anchor intermediate, called KO-2 that is competent for protein attachment. KO-2 
has an abnormal glycan structure with most likely four mannoses and EtN-P on Man1 and Man3 
(38). An additional EtN-P on mannose 2 might be transitory and is a potential substrate for 
PGAP5. Because of this abnormal glycan structure we speculate that PIG-O deficient cells might 
have a defect in sorting of free or protein anchored GPIs into ER exit sites (ERES). The ER exit 
of GPI anchored proteins is controlled by glycan remodeling and p24 complexes act as cargo 
receptors for GPI anchor sorting into COPII vesicles (6, 39, 49). In agreement with this model, 
we observed a global increase in HexCer levels in the remodeling mutants PGAP1, PGAP5 as 
well as for the p24 family proteins. We did however not detect an increase in GM3 levels in PIG-
O depleted cells, which shows that a global increase in HexCer does not necessarily translate into 
an increase in GM3 and most likely follows a different mechanism. In yeast it has been shown 
that the unfolded protein response is highly activated in the GPI remodeling mutants (40-42). 
Here we show that ER stress markers such as CHOP are upregulated in the GPI anchor 
remodeling and trafficking mutants including PIG-O but not in PIG-F deficient cells (Fig 8C). 
Recently we have shown that ceramide levels are increased in response to induction of the 
unfolded protein response (27). Since HexCer synthesis protects against Cer-induced stress in 
mammalian cells (50, 51) we speculate that the ER stress response might cause the observed 
increase in HexCer levels in the GPI anchor remodeling mutants. 
	   25	  
Finally, we did not observe any sphingolipid changes for the GPI anchor mutant PGAP2, which 
has normal GPI anchor biosynthesis in the ER but greatly reduced surface expression levels of 
GPI anchored proteins due to secretion (31). Sorting of GPI-APs into ERES and ER to Golgi 
trafficking is not affected in the PGAP2 deficient cells.  
Concerning the sterol composition of the GPI anchor deficient cells we observed no effect on 
free cholesterol levels but found a decrease in cholesterol ester (CE) levels in certain GPI anchor 
deficient cells (Fig. 9). There was however no correlation between the sterol and the HexCer 
profile since PIG-U deficient cells showed a similar reduction of CE levels as PIG-F deficient 
cells. In contrast, PGAP2 and PIG-O deficient cells, which synthesize GPI anchored proteins had 
almost wild type levels of CEs. We therefore speculate that the decrease in cholesterol ester is 
due to the absence of certain GPI anchored proteins that affect biosynthesis or degradation of 
cholesterol esters. In addition, uptake of cholesterol from the medium, which contains fetal calf 
serum might be affected in cells that lack GPI anchored proteins. 
GPI-anchored proteins have been postulated to segregate into sphingolipid enriched lipid ordered 
microdomains (52). In yeast it has been shown that ongoing ceramide synthesis is required for 
GPI-anchored protein transport from the ER to the Golgi compartment, linking the two processes 
(10, 11). In mammalian cells however de novo sphingolipid biosynthesis is not required to 
transport mammalian GPI-APs from the ER to the Golgi (15, 53). However, this does not 
exclude the possibility that also in mammalian cells ER to Golgi transport of ceramide is linked 
to the transport of GPI anchored proteins. It might be possible that under sphingolipid depleted 
conditions GPI anchored proteins are trafficked normally but that in the absence of GPI anchored 
proteins very long chain ceramides are not transported properly.  
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Taken together we present here a model whereby the levels of very long chain GlcCer are 
correlated to the biosynthesis of GPI anchor molecules. We propose that very long chain GlcCer 
levels and to some extent also very long chain sphingomyelin levels are linked to GPI 
biosynthesis to ensure that proportional amounts of each lipid class are synthesized and 
transported. 
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Figure legends 
 
Figure 1 Glucosylceramide profile of GPI-anchor deficient CHO cells. 
(A) Total GlcCer levels in F21 (wild type) and GPI-anchor mutants DPM3, PIG-X, PIG-F and 
PGAP2. (B) Total GlcCer levels in C311 (wild type) and GPI-anchor mutant cell lines PIG-O 
and PIG-U. (C) Individual GlcCer profile of GPI anchor mutants from the F21 series and (D) 
mutants from the C311 series. 
 
Figure 2 Complementation of the GPI anchor mutants PIG-F and PIG-U 
(A) Biosynthetic pathway of mammalian GPI-APs.	  (1) GPI-N-acetylglucosamine transferase, (2) 
GlcNAc-PI de-N-acetylase (PIG-L), (3) Flippase, (4) Inositol acyltransferase, (5) PI remodeling 
enzyme, (6) GPI-MT I (PIG-M/PIG-X), (7) GPI-MT II, (8) EtN-P transferase I, (9) GPI-MT III, 
(10) EtN-P transferase III (PIG-O/PIG-F), (11) EtN-P transferase II (PIG-G/PIG-F), (12) GPI 
transamidase (PIG-K, GAA1, PIG-S, PIG-T, PIG-U), (13) Inositol deacylase (PGAP1), (14) 
EtN-P Phosphoesterase (PGAP5). l  decreased levels of HexCer, l  unchanged levels of 
HexCer, l  elevated levels of HexCer. Red arrows indicate a reduction in cholesterol ester levels.	  
(B) Left panel: PIG-F mutant CHO cells (CHO PIG-F -/-) stably expressing Venus-CD59. Right 
panel: PIG-F mutant CHO cells (CHO PIG-F -/-) stably expressing Venus-CD59 and human 
PIG-F. Bar = 10 µm. (C) Relative GlcCer levels in the GPI-anchor mutants PIG-F and PIG-U 
and in the complemented PIG-Fc and PIG-Uc cells. GlcCer levels were calculated as percentage 
of PIG-Fc and PIG-Uc respectively. *p < 0.05 uncomplemented versus complemented cells. 
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Figure 3 HexCer profile of GPI anchor deficient HeLa cells. 
(A) Total HexCer levels of HeLa cells treated with siRNA against PIG-L, DPM3, PIG-X, PIG-F, 
PIG-O, PIG-U or PGAP2, respectively. Scrambled (SCR) siRNA was used as control. Cells were 
harvested 72 h after transfection. (B) Individual HexCer levels of the GPI anchor deficient HeLa 
cells. *p < 0.05 and **p < 0.01 SCR versus siRNA treated cells. 
 
Figure 4 GM3 levels of GPI-anchor mutant CHO cells  
(A) Individual GM3 profile of wild type (F21) and GPI-anchor mutant cell lines DPM3, PIG-X, 
PIG-F and PGAP2. (B) Individual GM3 profile of wild type (C311) and GPI-anchor mutant PIG-
O and PIG-U cells. *p < 0.05 wild type versus GPI anchor mutant. 
 
Figure 5 Ceramide profile of GPI anchor deficient cells  
(A) Total ceramide (Cer) levels in F21 wild type and GPI-anchor mutants DPM3, PIG-X, PIG-F 
and PGAP2. (B) Total Cer levels in C311 wild type and GPI-anchor mutant cell lines PIG-O and 
PIG-U. (C) Individual Cer profile of GPI anchor mutants from the F21 series and (D) mutants 
from the C311 series. (E) Total Cer and (F) individual Cer levels of HeLa cells treated with 
siRNA against PIG-L, DPM3, PIG-X, PIG-F, PIG-O, PIG-U or PGAP2, respectively. Scrambled 
(SCR) siRNA was used as control. ***p < 0.005 wild type versus GPI anchor mutant. (G) 
Ceramide glycosylation assay: HeLa cells were treated with siRNA against PIG-F, PIG-O and 
PIG-U respectively. After 70h, cells were incubated with NBD C6-Cer for 2h after which 
sphingolipids were extracted. Lipid extracts were resolved on borate impregnated HPTLC plates 
and visualized under UV exposure. Standards were NBD C6-Cer, NBD C6-GlcCer and NBD C6 
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GalCer. Bands were quantified with Image J software and values were calculated as percentage 
of input (NBD C6-Cer). 
 
Figure 6 Sphingomyelin levels do not change in the GPI deficient cells  
(A) Total sphingomyelin (SM) levels of F21 wild type and GPI-anchor mutant cell lines DPM3, 
PIG-X, PIG-F and PGAP2. (B) Total SM levels of C311 wild type and GPI-anchor mutant cell 
lines PIG-O and PIG-U. (C) Individual SM levels in the F21 series of GPI anchor mutants. (D) 
Total SM levels of Hela cells treated with siRNA gainst PIG-L, DPM3, PIG-X, PIG-F, PIG-O, 
PIG-U and PGAP2. Scrambled (SCR) siRNA was used as control. (E) Individual SM profile of 
GPI anchor deficient HeLa cells.  
 
Figure 7 CERT knockdown does not lead to a decrease in HexCer levels. 
(A) Total sphingomyelin and HexCer levels of Hela cells treated with siRNA against the 
ceramide transport protein CERT. Scrambled (SCR) siRNA was used as control. (B) Individual 
sphingomyelin profile of HeLa cells treated with siRNA against CERT. **p < 0.01 SCR versus 
siRNA knockdown. 
 
Figure 8 HexCer levels are affected by GPI glycan remodeling and involve the p24 family 
members 
(A) Total HexCer levels of Hela cells treated with siRNA against PGAP1, PGAP5, p23 or p24, 
respectively. Scrambled (SCR) siRNA was used as control. (B) Detailed HexCer profile of the 
corresponding cells. (C) Real time RT-PCR analysis of genes involved in UPR induction. HeLa 
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cells were treated with siRNA against PIG-F, PIG-O, PGAP1, PGAP5, p23 and p24. SCR was 
used as control. Cells were harvested 72h after transfection and total RNA was isolated. Relative 
levels of CHOP and BiP were assessed by qRT-PCR. 
 
Figure 9 Sterol levels in the GPI anchor deficient cells  
(A) Free cholesterol and cholesterol ester levels in in the GPI-anchor deficient CHO cell lines 
DPM3, PIG-X, PIG-F, PIG-O and PIG-U. Values were calculated as percentage of wild type 
(F21 or C311 respectively). (B) Free cholesterol and cholesterol ester levels in HeLa cells after a 
transient knockdown of the GPI anchor biosynthesis genes PIG-L, DPM3, PIG-F PIG-O and 
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